Results 31 to 40 of about 61,573 (234)
Background: is an increasingly important cause of nosocomial infections worldwide. In addition to the intrinsic resistance of to many antibiotics, available treatment approaches with older antibiotics are significantly associated with an increase in ...
Valadan Tahbaz, Sahel +3 more
doaj +1 more source
Introduction: In view of the continuous rise in Gram-negative bacterial resistance and limited treatment options, Ceftolozane/tazobactam (C/T) is a newly introduced antimicrobial agent in Lebanon for its demonstrated activity against resistant Gram ...
George F Araj +3 more
doaj +1 more source
Background: The emergence of antibiotic resistance is increasing and there are few effective antibiotics to treat infections caused by resistant and multidrug resistant bacterial pathogens.
Felipe Francisco Tuon +4 more
doaj +1 more source
SINGLE-DOSE TOXICITY STUDIES OF TAZOBACTAM/PIPERACILLIN AND TAZOBACTAM
Tazobactam (TAZ) is a newly developed beta-lactamase inhibitor. Tazobactam/Piperacillin (TAZ/PIPC) is a formulation consisting of TAZ and PIPC in a ratio of 1:4. Singe-dose toxicity studies in TAZ/PIPC and TAZ were carried out using mice and rats of both sexes and male dogs. The results were as follows. 1.
HAYASHI, Taiji +7 more
openaire +3 more sources
OBJECTIVE: To compare the activity of piperacillin/tazobactam with that of other broad parenteral antibiotics against aerobic and facultative anaerobic blood culture isolates in a Canada-wide ...
Kevin R Forward +5 more
core +1 more source
Study of the Comparative Activity of Piperacillin/Tazobactam with Currently Available Antibiotics against 8206 Aerobic Isolates [PDF]
OBJECTIVES: To compare the activity of piperacillin-tazobactam with piperacillin and other parenterally administered antibiotics against aerobic Gram-negative bacilli and Gram-positive cocci isolated from across Canada, and to determine the prevalence of
Kevin R Forward +6 more
core +1 more source
Pulmonary penetration of piperacillin and tazobactam in critically ill patients.
Pulmonary infections in critically ill patients are common and are associated with high morbidity and mortality. Piperacillin–tazobactam is a frequently used therapy in critically ill patients with pulmonary infection.
Goodwin, J +7 more
core +1 more source
Pharmacokinetics of Piperacillin and Tazobactam.
Pharmacokinetics of Piperacillin and Tazobactam.
Omar Vesga (248534) +4 more
core +1 more source
The impact of medication shortages on paediatric care: A retrospective impact analysis
Aims Medication shortages are a growing global concern, with potentially greater consequences in paediatric patients because of the limited availability of safe, evidence‐based and appropriately formulated medication. This study aimed to evaluate the impact of medication shortages on paediatric patients by assessing the suitability and safety of ...
Maaike Johanna Rutten ‐ van Kranenburg +6 more
wiley +1 more source
: Objectives: Ceftolozane/tazobactam is a cephalosporin/β-lactamase inhibitor combination with activity against Gram-negative bacilli. Here we report the use of ceftolozane/tazobactam in Canada using a national registry. Methods: The CLEAR registry uses
George G. Zhanel +15 more
doaj +1 more source

